E
7.05
0.08 (1.15%)
| Previous Close | 6.97 |
| Open | 6.97 |
| Volume | 227,318 |
| Avg. Volume (3M) | 246,181 |
| Market Cap | 154,117,232 |
| Price / Sales | 2.28 |
| Price / Book | 24.07 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 |
| Profit Margin | -27.34% |
| Operating Margin (TTM) | -21.71% |
| Diluted EPS (TTM) | -0.840 |
| Quarterly Revenue Growth (YOY) | 7.50% |
| Total Debt/Equity (MRQ) | 367.92% |
| Current Ratio (MRQ) | 2.32 |
| Operating Cash Flow (TTM) | -14.91 M |
| Levered Free Cash Flow (TTM) | -10.11 M |
| Return on Assets (TTM) | -19.21% |
| Return on Equity (TTM) | -117.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Exagen Inc. | Mixed | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 0.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.13 |
|
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 19.82% |
| % Held by Institutions | 45.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Palumbo Wealth Management Llc | 31 Mar 2025 | 99,205 |
| Stonepine Capital Management, Llc | 31 Mar 2025 | 95,747 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (Canaccord Genuity, 13.48%) | Buy |
| Median | 7.50 (6.38%) | |
| Low | 7.00 (Cantor Fitzgerald, -0.71%) | Buy |
| Average | 7.50 (6.38%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 15 May 2025 | 7.00 (-0.71%) | Buy | 5.74 |
| Canaccord Genuity | 13 May 2025 | 8.00 (13.48%) | Buy | 5.63 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Jun 2025 | Announcement | Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics |
| 09 May 2025 | Announcement | Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares |
| 08 May 2025 | Announcement | Exagen Inc. Prices Public Offering of Common Stock |
| 07 May 2025 | Announcement | Exagen Inc. Announces Proposed Public Offering of Common Stock |
| 05 May 2025 | Announcement | Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume |
| 28 Apr 2025 | Announcement | Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors |
| 21 Apr 2025 | Announcement | Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |